|Principal Investigator: Jenny Workman|
|Keywords: Clinical Trial , Pediatrics||Department: Pediatric Administration|
|IRB Number: 00130346|
|Specialty: Pediatrics, General|
|Recruitment Status: Recruiting|
The long-term goal of this research is to improve outcomes of children with septic shock. The overall objective is to conduct a multi-center, international trial examining adjunctive hydrocortisone treatment of children with refractory septic shock. The investigators hypothesize that hydrocortisone, compared to placebo, will decrease the proportion of subjects with poor outcomes, defined as death or severe, residual HRQL decrement, 28 days following study enrollment. The investigators further hypothesize that this beneficial effect will be realized in the absence of significant adverse events potentially attributable to hydrocortisone. We will test the hypothesis that biomarker-based prognostic and predictive enrichment strategies can improve our ability to identify which children with septic shock are more likely to benefit from adjunctive hydrocortisone.